Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

DHR vs A vs TMO vs WAT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DHR
Danaher Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$123.80B
5Y Perf.+18.4%
A
Agilent Technologies, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$33.31B
5Y Perf.+74.9%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$175.76B
5Y Perf.+35.4%
WAT
Waters Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$22.78B
5Y Perf.+2.5%

DHR vs A vs TMO vs WAT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DHR logoDHR
A logoA
TMO logoTMO
WAT logoWAT
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$123.80B$33.31B$175.76B$22.78B
Revenue (TTM)$24.78B$7.07B$45.20B$3.77B
Net Income (TTM)$3.69B$1.29B$6.86B$449M
Gross Margin60.7%38.8%39.4%55.0%
Operating Margin21.0%20.6%17.8%17.1%
Forward P/E20.7x19.7x19.0x24.3x
Total Debt$18.42B$3.35B$40.85B$1.41B
Cash & Equiv.$4.62B$1.79B$9.86B$588M

DHR vs A vs TMO vs WATLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DHR
A
TMO
WAT
StockMay 20May 26Return
Danaher Corporation (DHR)100118.4+18.4%
Agilent Technologie… (A)100133.5+33.5%
Thermo Fisher Scien… (TMO)100135.4+35.4%
Waters Corporation (WAT)100174.9+74.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: DHR vs A vs TMO vs WAT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: A leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Danaher Corporation is the stronger pick specifically for capital preservation and lower volatility. TMO and WAT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
DHR
Danaher Corporation
The Defensive Pick

DHR is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 0.94, Low D/E 35.1%, current ratio 1.87x
  • Beta 0.94 vs A's 1.23, lower leverage
Best for: sleep-well-at-night
A
Agilent Technologies, Inc.
The Income Pick

A carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 10 yrs, beta 1.23, yield 0.8%
  • PEG 1.34 vs DHR's 34.20
  • Beta 1.23, yield 0.8%, current ratio 1.96x
  • Lower P/E (19.7x vs 24.3x), PEG 1.34 vs 4.69
Best for: income & stability and valuation efficiency
TMO
Thermo Fisher Scientific Inc.
The Long-Run Compounder

TMO is the clearest fit if your priority is long-term compounding.

  • 229.1% 10Y total return vs DHR's 218.0%
  • +16.6% vs DHR's -7.2%
Best for: long-term compounding
WAT
Waters Corporation
The Growth Play

WAT is the clearest fit if your priority is growth exposure.

  • Rev growth 7.0%, EPS growth 0.5%, 3Y rev CAGR 2.1%
  • 7.0% revenue growth vs DHR's 2.9%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthWAT logoWAT7.0% revenue growth vs DHR's 2.9%
ValueA logoALower P/E (19.7x vs 24.3x), PEG 1.34 vs 4.69
Quality / MarginsA logoA18.3% margin vs WAT's 11.9%
Stability / SafetyDHR logoDHRBeta 0.94 vs A's 1.23, lower leverage
DividendsA logoA0.8% yield, 10-year raise streak, vs TMO's 0.4%, (1 stock pays no dividend)
Momentum (1Y)TMO logoTMO+16.6% vs DHR's -7.2%
Efficiency (ROA)A logoA10.1% ROA vs DHR's 4.5%, ROIC 13.5% vs 5.9%

DHR vs A vs TMO vs WAT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DHRDanaher Corporation
FY 2025
Revenue from Contract with Customer, Measurement, Recurring
81.9%$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring
18.1%$4.4B
AAgilent Technologies, Inc.
FY 2025
Agilent CrossLab
41.9%$2.9B
Life Sciences and Applied Markets
39.2%$2.7B
Applied Markets
18.9%$1.3B
TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B
WATWaters Corporation
FY 2025
Waters Instrument Systems
34.8%$1.1B
Waters Service
34.1%$1.1B
Chemistry Consumables
19.9%$631M
Ta Instrument Systems
7.7%$244M
Ta Service
3.4%$108M

DHR vs A vs TMO vs WAT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDHRLAGGINGTMO

Income & Cash Flow (Last 12 Months)

DHR leads this category, winning 3 of 6 comparable metrics.

TMO is the larger business by revenue, generating $45.2B annually — 12.0x WAT's $3.8B. A is the more profitable business, keeping 18.3% of every revenue dollar as net income compared to WAT's 11.9%. On growth, WAT holds the edge at +91.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDHR logoDHRDanaher Corporati…A logoAAgilent Technolog…TMO logoTMOThermo Fisher Sci…WAT logoWATWaters Corporation
RevenueTrailing 12 months$24.8B$7.1B$45.2B$3.8B
EBITDAEarnings before interest/tax$7.2B$1.7B$10.5B$953M
Net IncomeAfter-tax profit$3.7B$1.3B$6.9B$449M
Free Cash FlowCash after capex$5.3B$993M$6.7B$264M
Gross MarginGross profit ÷ Revenue+60.7%+38.8%+39.4%+55.0%
Operating MarginEBIT ÷ Revenue+21.0%+20.6%+17.8%+17.1%
Net MarginNet income ÷ Revenue+14.9%+18.3%+15.2%+11.9%
FCF MarginFCF ÷ Revenue+21.4%+14.1%+14.9%+7.0%
Rev. Growth (YoY)Latest quarter vs prior year+3.7%+7.0%+6.2%+91.5%
EPS Growth (YoY)Latest quarter vs prior year+9.8%-3.6%+11.3%-142.9%
DHR leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

DHR leads this category, winning 3 of 7 comparable metrics.

At 25.8x trailing earnings, A trades at a 26% valuation discount to DHR's 34.7x P/E. Adjusting for growth (PEG ratio), A offers better value at 1.75x vs DHR's 34.20x — a lower PEG means you pay less per unit of expected earnings growth.

MetricDHR logoDHRDanaher Corporati…A logoAAgilent Technolog…TMO logoTMOThermo Fisher Sci…WAT logoWATWaters Corporation
Market CapShares × price$123.8B$33.3B$175.8B$22.8B
Enterprise ValueMkt cap + debt − cash$137.6B$34.9B$206.8B$23.6B
Trailing P/EPrice ÷ TTM EPS34.71x25.75x26.66x32.48x
Forward P/EPrice ÷ next-FY EPS est.20.73x19.71x19.04x24.30x
PEG RatioP/E ÷ EPS growth rate34.20x1.75x12.62x6.27x
EV / EBITDAEnterprise value multiple18.14x19.74x18.99x21.47x
Price / SalesMarket cap ÷ Revenue5.04x4.79x3.94x7.20x
Price / BookPrice ÷ Book value/share2.37x4.96x3.33x8.15x
Price / FCFMarket cap ÷ FCF23.54x28.92x27.93x42.21x
DHR leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

WAT leads this category, winning 4 of 9 comparable metrics.

A delivers a 18.7% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs WAT's 4/9, reflecting strong financial health.

MetricDHR logoDHRDanaher Corporati…A logoAAgilent Technolog…TMO logoTMOThermo Fisher Sci…WAT logoWATWaters Corporation
ROE (TTM)Return on equity+7.1%+18.7%+13.2%+8.0%
ROA (TTM)Return on assets+4.5%+10.1%+6.4%+4.6%
ROICReturn on invested capital+5.9%+13.5%+7.5%+20.3%
ROCEReturn on capital employed+7.0%+14.5%+9.1%+18.5%
Piotroski ScoreFundamental quality 0–97564
Debt / EquityFinancial leverage0.35x0.50x0.76x0.55x
Net DebtTotal debt minus cash$13.8B$1.6B$31.0B$820M
Cash & Equiv.Liquid assets$4.6B$1.8B$9.9B$588M
Total DebtShort + long-term debt$18.4B$3.4B$40.9B$1.4B
Interest CoverageEBIT ÷ Interest expense18.13x19.53x5.89x6.72x
WAT leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

WAT leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in WAT five years ago would be worth $11,311 today (with dividends reinvested), compared to $7,907 for DHR. Over the past 12 months, TMO leads with a +16.6% total return vs DHR's -7.2%. The 3-year compound annual growth rate (CAGR) favors WAT at 5.6% vs DHR's -5.6% — a key indicator of consistent wealth creation.

MetricDHR logoDHRDanaher Corporati…A logoAAgilent Technolog…TMO logoTMOThermo Fisher Sci…WAT logoWATWaters Corporation
YTD ReturnYear-to-date-23.9%-14.3%-20.1%-8.5%
1-Year ReturnPast 12 months-7.2%+12.8%+16.6%+3.1%
3-Year ReturnCumulative with dividends-15.9%-9.0%-11.9%+17.9%
5-Year ReturnCumulative with dividends-20.9%-7.7%+2.1%+13.1%
10-Year ReturnCumulative with dividends+218.0%+202.6%+229.1%+163.2%
CAGR (3Y)Annualised 3-year return-5.6%-3.1%-4.2%+5.6%
WAT leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — DHR and WAT each lead in 1 of 2 comparable metrics.

DHR is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than A's 1.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WAT currently trades 84.4% from its 52-week high vs DHR's 72.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDHR logoDHRDanaher Corporati…A logoAAgilent Technolog…TMO logoTMOThermo Fisher Sci…WAT logoWATWaters Corporation
Beta (5Y)Sensitivity to S&P 5000.94x1.23x1.10x1.07x
52-Week HighHighest price in past year$242.80$160.27$643.99$414.15
52-Week LowLowest price in past year$172.06$104.36$385.46$275.05
% of 52W HighCurrent price vs 52-week peak+72.0%+73.4%+73.4%+84.4%
RSI (14)Momentum oscillator 0–10032.352.239.862.7
Avg Volume (50D)Average daily shares traded4.1M2.0M1.9M989K
Evenly matched — DHR and WAT each lead in 1 of 2 comparable metrics.

Analyst Outlook

A leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: DHR as "Buy", A as "Buy", TMO as "Buy", WAT as "Hold". Consensus price targets imply 41.2% upside for DHR (target: $247) vs 15.2% for WAT (target: $403). For income investors, A offers the higher dividend yield at 0.84% vs TMO's 0.36%.

MetricDHR logoDHRDanaher Corporati…A logoAAgilent Technolog…TMO logoTMOThermo Fisher Sci…WAT logoWATWaters Corporation
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$247.00$166.00$654.67$402.57
# AnalystsCovering analysts42384234
Dividend YieldAnnual dividend ÷ price+0.7%+0.8%+0.4%
Dividend StreakConsecutive years of raises11081
Dividend / ShareAnnual DPS$1.23$0.99$1.69
Buyback YieldShare repurchases ÷ mkt cap+2.5%+1.3%+1.7%+0.1%
A leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

DHR leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). WAT leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.

Best OverallDanaher Corporation (DHR)Leads 2 of 6 categories
Loading custom metrics...

DHR vs A vs TMO vs WAT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DHR or A or TMO or WAT a better buy right now?

For growth investors, Waters Corporation (WAT) is the stronger pick with 7.

0% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Agilent Technologies, Inc. (A) offers the better valuation at 25. 8x trailing P/E (19. 7x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DHR or A or TMO or WAT?

On trailing P/E, Agilent Technologies, Inc.

(A) is the cheapest at 25. 8x versus Danaher Corporation at 34. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 34x versus Danaher Corporation's 34. 20x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — DHR or A or TMO or WAT?

Over the past 5 years, Waters Corporation (WAT) delivered a total return of +13.

1%, compared to -20. 9% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TMO returned +229. 1% versus WAT's +163. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DHR or A or TMO or WAT?

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

94β versus Agilent Technologies, Inc. 's 1. 23β — meaning A is approximately 31% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — DHR or A or TMO or WAT?

By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.

0% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, WAT leads at 2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DHR or A or TMO or WAT?

Waters Corporation (WAT) is the more profitable company, earning 20.

3% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 18. 2% for TMO. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DHR or A or TMO or WAT more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 34x versus Danaher Corporation's 34. 20x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 24. 3x for Waters Corporation — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 41. 2% to $247. 00.

08

Which pays a better dividend — DHR or A or TMO or WAT?

In this comparison, A (0.

8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. WAT does not pay a meaningful dividend and should not be held primarily for income.

09

Is DHR or A or TMO or WAT better for a retirement portfolio?

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94), 0. 7% yield, +218. 0% 10Y return). Both have compounded well over 10 years (DHR: +218. 0%, WAT: +163. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DHR and A and TMO and WAT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

DHR, A pay a dividend while TMO, WAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DHR

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 8%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

A

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 10%
Run This Screen
Stocks Like

TMO

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 9%
Run This Screen
Stocks Like

WAT

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 45%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform DHR and A and TMO and WAT on the metrics below

Revenue Growth>
%
(DHR: 3.7% · A: 7.0%)
Net Margin>
%
(DHR: 14.9% · A: 18.3%)
P/E Ratio<
x
(DHR: 34.7x · A: 25.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.